stockrowZoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024.
- Revenue
- −0.24%
- EPS
- +2.48%
- Free cash flow
- +17.4%
- Total debt
- +37.5%
Quarter to June 2026, against a year earlier
Follow ZTS
Alert me
Zoetis Inc. (ZTS) Return on assets
Zoetis Inc.'s return on assets over the twelve months to 30 June 2026 was 17.8%, down 0.2 percentage points from fiscal 2025 (18.0%). Over the past ten years it has ranged from 4.68% (fiscal 2015) to 18.0% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of −1.67% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 18.0% | 0.57 |
| FY2024 | 17.4% | 1.38 |
| FY2023 | 16.1% | 1.38 |
| FY2022 | 14.7% | (0.14) |
| FY2021 | 14.8% | 1.79 |
| FY2020 | 13.0% | (0.42) |
| FY2019 | 13.4% | (1.31) |
| FY2018 | 14.8% | 4.11 |
| FY2017 | 10.6% | 0.09 |
| FY2016 | 10.6% | 5.87 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ZTS Zoetis Inc. | 17.8% |
| UTHR United Therapeutics Corporation compare | 17.1% |
| NBIX Neurocrine Biosciences, Inc. compare | 14.2% |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.44% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 1.27% |
| TAK Takeda Pharmaceutical Co. compare | 0.00% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| ELAN Elanco Animal Health Incorporated compare | −1.46% |
| VTRS Viatris Inc. compare | −1.67% |
| Drug Manufacturers Specialty & Generic industry median | −1.67% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ZTS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement